ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Official Title  A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for colorectal cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.

Detailed Description

OBJECTIVES:

  • Compare the overall survival of patients with locally advanced, locally recurrent, or metastatic colorectal cancer treated with oxaliplatin, fluorouracil, and leucovorin calcium versus irinotecan, after initial therapy with fluorouracil.
  • Determine the time to progression, time to treatment failure, and overall response rate in patients treated with these 2 regimens.
  • Determine the toxic effects of these 2 regimens in these patients.
  • Compare the quality of life of patients treated with these 2 regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to performance status (ECOG 0-1 vs 2), primary indicator lesion (hepatic vs pulmonary vs other), age (less than 65 vs at least 65 years), alkaline phosphatase (less than 2 vs at least 2 times ULN), fluorouracil failure (adjuvant vs metastatic), and membership (intergroup vs expanded participation project).

Patients are randomized to one of two treatment arms:

  • Arm I: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.

Patients who experience progression or toxicity on the initial regimen may crossover to the other regimen. At least 3 weeks must elapse between regimens.

Quality of life is assessed at baseline, prior to each chemotherapy course, at crossover, and at the end of the study.

Patients are followed every 6 months for 3 years or until death.

PROJECTED ACCRUAL: A total of 560 patients will be accrued for this study within 2 years.

Study Phase Phase III
Study Type  Interventional
Study Design  Treatment, Randomized, Active Control
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Colorectal Cancer
Intervention  Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
MEDLINE PMIDs 11204663
Links Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Active, not recruiting
Enrollment 
Start Date  November 1999
Completion Date
Eligibility Criteria 

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma not curable by surgery or radiotherapy
  • Progressive disease following:

    • One prior fluorouracil based chemotherapy regimen for metastatic disease OR
    • Failure during or within 6 months after fluorouracil based adjuvant therapy
  • Measurable or evaluable disease
  • No CNS metastases or carcinomatous meningitis

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • At least 12 weeks

Hematopoietic:

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9 g/dL (transfusion allowed)

Hepatic:

  • Bilirubin no greater than 1.5 mg/dL
  • AST no greater than 5 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 5 times ULN

Renal:

  • Creatinine no greater than 1.5 times ULN

Cardiovascular:

  • No uncontrolled high blood pressure
  • No unstable angina
  • No symptomatic congestive heart failure
  • No myocardial infarction with the past 6 months
  • No serious uncontrolled cardiac arrhythmias
  • No New York Heart Association class III or IV heart disease

Pulmonary:

  • No pleural effusion or ascites that cause respiratory compromise (e.g., dyspnea grade 2 or greater)
  • No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Fluent in English
  • No active or uncontrolled infection
  • No other prior malignancy within the past 5 years, except:
  • Adequately treated basal or squamous cell skin cancer
  • Adequately treated noninvasive carcinomas
  • No sensory neuropathy grade 2 or greater
  • No uncontrolled colonic or small bowel disorders (greater than 3 loose stools daily)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No concurrent sargramostim (GM-CSF)

Chemotherapy:

  • At least 4 weeks since prior chemotherapy and recovered
  • No more than 1 prior chemotherapy regimen for advanced colorectal cancer
  • No prior irinotecan or other camptothecin derivative (e.g., topotecan)
  • No prior oxaliplatin
  • No other concurrent investigational chemotherapy agents

Endocrine therapy:

  • Not specified

Radiotherapy:

  • At least 4 weeks since prior major radiotherapy
  • No prior radiotherapy to greater than 25% of bone marrow

Surgery:

  • At least 4 weeks since prior major surgery and recovered
  • At least 2 weeks since prior minor surgery and recovered
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States,   Canada,   South Africa
Administrative Information Fields
NCT ID  NCT00005036
Organization ID CDR0000067623
Secondary IDs †† NCCTG-N9841, ECOG-N9841, SWOG-N9841
Study Sponsor  North Central Cancer Treatment Group
Collaborators †† National Cancer Institute (NCI)
Southwest Oncology Group
Eastern Cooperative Oncology Group
Investigators 
Study Chair:     Henry C. Pitot, MD     Mayo Clinic    
Study Chair:     Philip A. Philip, MD, PhD, FRCP     Barbara Ann Karmanos Cancer Institute    
Study Chair:     Edith P. Mitchell, MD, FACP     Kimmel Cancer Center (KCC)    
Information Provided By National Cancer Institute (NCI)
Verification Date February 2004
First Received Date  April 6, 2000
Last Updated Date July 23, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers